I-ACEA Therapeutics

I-ACEA Therapeutics, ehlala eSan Diego, eCalifornia yinkampani ephethwe ngokupheleleyo yaseSorrento. I-ACEA Therapeutics izibophelele ekuphuhliseni nasekuziseni unyango olutsha lokuphucula ubomi bezigulana ezinezifo ezibeka ubomi esichengeni.

Ikhompawundi yethu ekhokelayo, i-Abivertinib, i-molecule kinase inhibitor, okwangoku iphantsi koqwalaselo yi-China Food and Drug Administration (CFDA) yonyango lwezigulane ezinomhlaza wemiphunga ye-cell (NSCLC) engeyiyo encinci equlethe ukuguqulwa kwe-EGFR T790M. Ikwakwizilingo zeklinikhi ukunyanga abaguli esibhedlele abane-Covid-19 eBrazil nase-US ekhokelwa Sorrento Therapeutics. Isibini esincinci se-molecule kinase inhibitor ye-ACEA, i-AC0058, ingene kwiSigaba 1B sophuhliso e-US kunyango lwe-systemic lupus erythematosus (SLE).

Kunye nombutho owomeleleyo we-R&D, i-ACEA iseke ukwenziwa kweziyobisi kunye nesakhono sorhwebo e-China ukuxhasa ukukhula kwethu kwexesha elide. Esi sibonelelo sibonelela ngolawulo olukhulu kwikhonkco lethu lokubonelela ukuqinisekisa ukuba iimveliso zisiwa kwizigulana kwangexesha.

SCILEX

I-SCILEX HOLDING COMPANY ("Scilex") , i-subsidiary yobuninzi be-Sorrento, izinikele ekuphuhliseni nasekuthengiseni iimveliso zokulawula iintlungu. Imveliso ephambili yenkampani ZTlido^® (i-lidocaine ye-topical system 1.8%), i-branded prescription ye-lidocaine yemveliso ye-topical evunywe yi-US Food and Drug Administration ukwenzela ukukhulula intlungu ehambelana ne-Post-Herpetic Neuralgia (PHN), eyindlela yobuhlungu be-nerve post-shingles.

I-Scilex's SP-102 (i-10 mg ye-dexamethasone sodium phosphate gel), okanye i-SEMDEXA™, yonyango lwe-Lumbar Radicular Pain ikwinkqubo yokugqiba uvavanyo lwezonyango lweSigaba sesi-III. Inkampani ilindele ukuba i-SP-102 ibe yi-FDA evunyiweyo yokuqala yokuvunywa kwenaliti ye-non-opioid epidural ukunyanga intlungu ye-lumbosacral radicular, okanye i-sciatica, enokuthi ithathe indawo ye-10 kwi-11 yezigidi ze-off-label epidural steroid injections ezilawulwa ngonyaka ngamnye e-US.

Bioserv

I-Bioserv, eseSan Diego, eCalifornia yinkampani ephethwe ngokupheleleyo yaseSorrento. Yasekwa ngo-1988, umbutho ngumboneleli wenkonzo yokwenziwa kwekhontrakthi ye-cGMP engaphezulu kwe-35,000 yeenyawo zesikwere seendawo ezinobuchule obuphambili obugxile kwi-aseptic kunye ne-non-aseptic bulk formulation; ukuhluza; ukuzaliswa; ukumisa; iinkonzo ze-lyophilization; ukuleyibhela ukudibanisa iimpahla ezigqityiweyo; iikiti kunye nokupakishwa; kunye nokugcinwa kweqondo lokushisa elilawulwayo kunye neenkonzo zokuhambisa ukuxhasa i-Pre-Clinical, iSigaba soku-I kunye ne-II seemveliso zamachiza ovavanyo lwezonyango, izixhobo zonyango, ii-reagents zokuxilonga zonyango kunye neekiti, kunye ne-reagents yesayensi yobomi.

Concortis-Levena

Ngo-2008, i-Concortis Biosystems yasekwa ngenjongo yokusebenzela ngcono inzululwazi kunye noluntu loxubo-mayeza olunomgangatho ophezulu we-antibody drug conjugate (ADC) reagents kunye neenkonzo. Ngo-2013, i-Sorrento yafumana i-Concortis, idala inkampani ephezulu ye-ADC. Indibaniselwano ye-G-MAB™ (ithala leencwadi le-antibody ngokupheleleyo) kunye ne-Concortis yobunini betyhefu, izinxibelelanisi, kunye neendlela zokudibanisa inamandla okuvelisa ii-ADC ezikhokelayo kushishino, isizukulwana se-3.

I-Concortis ngoku iphonononga ngaphezu kwe-20 yeenketho ezahlukeneyo ze-ADC (ngaphambi kweklinikhi) kunye nezicelo kwi-oncology nangaphezulu. Ngomhla we-19 ku-Okthobha ka-2015, i-Sorrento yabhengeza ukuyilwa kwe-Levena Biopharma njengequmrhu elizimeleyo ukunika imarike uluhlu olubanzi lweenkonzo ze-ADC ukususela ekuqalisweni kweprojekthi ye-ADC ngokwenziwa kwe-cGMP yee-ADCs ukuya kwisigaba I/II sezifundo zeklinikhi. Ngolwazi oluneenkcukacha, nceda undwendwele www.levenabiopharma.com

I-SmartPharm Therapeutics, Inc

I-SmartPharm Therapeutics, Inc. (“i-SmartPharm”), inkampani ephantsi kwayo yonke. Sorrento Therapeutics, Inc. (Nasdaq: SRNE), linqanaba lophuhliso lwenkampani ye-biopharmaceutical egxile kwisizukulwana esilandelayo, unyango lwemfuza olungenantsholongwane kunyango lwezifo ezinzulu okanye ezinqabileyo ngombono wokudala "ibhayoloji ngaphakathi." I-SmartPharm okwangoku iphuhlisa inoveli, i-DNA-encoded monoclonal antibody ukuthintela usulelo nge-SARS-CoV-2, intsholongwane ebangela i-COVID-19 phantsi kwekhontrakthi kunye ne-Arhente yeeProjekthi zoPhando oluPhezulu lweSebe lezoKhuselo laseMelika. I-SmartPharm iqalise ukusebenza kwi-2018 kwaye ikomkhulu eCambridge, MA, USA.

Umkhombe Animal Health

I-Ark Animal Health yi-subsidiary ephethwe ngokupheleleyo ye-Sorrento. Umkhombe wasekwa ngo-2014 ukuzisa iqabane kwimarike yezilwanyana izisombululo ezintsha ezikhutshwe kuphando yoluntu kunye nemisebenzi yophuhliso Sorrento. Ilungiselelwe ukuba ibe ngumbutho ozimeleyo kunye nokuzimela ngokupheleleyo xa sele ifikelele kwinqanaba lezorhwebo (iimveliso ezilungele ukufumana imvume ye-FDA).

Inkqubo yophuhliso lwe-Ark's lead (ARK-001) yithamo enye ye-resiniferatoxin (RTX) isisombululo esitofwayo esingenazintsholongwane. I-ARK-001 ifumene i-FDA CVM (iZiko leVeterinary Medicine) i-MUMS (ukusetyenziswa okuncinci / iintlobo ezincinci) ukutyunjwa kokulawulwa kweentlungu zomhlaza wethambo kwizinja. Ezinye iiprojekthi ziquka izibonakaliso ezongezelelweyo ze-RTX kwiindawo ezinjengeentlungu ezingapheliyo ze-articular kwizilwanyana ezihamba kunye, intlungu ye-neuropathic kumahashe, kunye ne-idiopathic cystitis kwiikati, kunye nokuhlola amathuba ophuhliso kwindawo yezifo ezithathelwanayo okanye unyango lomhlaza.

IVirexHealth